Influence of granulocyte colony-stimulating factor on cardiac function in patients with acute myocardial infarction
Shi-Zun Guo1, Ning-Fu Wang, Liang Zhou
1Department of Cardiology, First Municipal Hospital of Hangzhou & Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, Zhejiang, 310006, China. eagle_sd@163.com
Insights
Subcutaneous granulocyte colony-stimulating factor (G-CSF) injection is safe for patients with ST-segment elevation myocardial infarction (STEMI). While G-CSF did not significantly improve cardiac function compared to controls, it showed potential for myocardial recovery.
Area of Science:
- Cardiology
- Regenerative Medicine
- Stem Cell Biology
Background:
- Granulocyte colony-stimulating factor (G-CSF) is explored for improving cardiac function post-myocardial infarction.
- Previous clinical trials on G-CSF for cardiac repair yielded controversial results.
- This study focuses on the safety and efficacy of subcutaneous G-CSF in STEMI patients with impaired left ventricular function.
Purpose of the Study:
- To evaluate the safety and efficacy of subcutaneous G-CSF injection.
- To assess the impact of G-CSF on left ventricular function after ST-segment elevation myocardial infarction (STEMI).
- To investigate G-CSF's role in stem cell mobilization for myocardial repair.
Main Methods:
- Thirty-three STEMI patients with leukopenia were randomized post-percutaneous coronary intervention.
- The G-CSF group received daily subcutaneous injections (10 microg/kg) for 7 days.
- Outcomes included blood analyses, echocardiography, angiography, and adverse event monitoring at 6-month follow-up.
Main Results:
- No severe adverse events were reported in either the G-CSF or control group.
- Both groups showed significant improvements in segmental wall thickening and left ventricular ejection fraction.
- No significant differences in cardiac function recovery were observed between the G-CSF and control groups, except for a significant difference in left ventricular ejection fraction measured by angiocardiography (P = 0.046).
Conclusions:
- Subcutaneous G-CSF administration is safe for STEMI patients.
- G-CSF appears to be a pragmatic strategy for myocardial global function recovery.
- Further research may elucidate G-CSF's specific benefits in stem cell mobilization for cardiac repair.
Background:
Granulocyte colony-stimulating factor (G-CSF) seems to improve cardiac function and perfusion when used systemically through mobilization of stem cells into peripheral blood, but results of previous clinical trials remain controversial. This study was designed to investigate safety and efficacy of subcutaneous injection of G-CSF on left ventricular function in patients with impaired left ventricular function after ST-segment elevation myocardial infarction (STEMI).
Methods:
Thirty-three patients (22 men; age, (68.5 +/- 6.1) years) with STEMI and with comorbidity of leukopenia were included after successful primary percutaneous coronary intervention within 12 hours after symptom onset. Patients were randomized into G-CSF group who received G-CSF (10 microg/kg of body weight, daily) for continuous 7 days and control group. Results of blood analyses, echocardiography and angiography were documented as well as possibly occurred adverse events.
Results:
No severe adverse events occurred in both groups. Mean segmental wall thickening in infract segments increased significantly at 6-month follow up compared with baseline in both groups, but the longitudinal variation between two groups had no significant difference (P > 0.05). The same change could also be found in longitudinal variation of wall motion score index of infarct segments (P > 0.05). At 6-month follow-up, left ventricular end-diastolic volume of both groups increased to a greater extent, but there were no significant differences between the two groups when comparing the longitudinal variations (P > 0.05). In both groups, left ventricular ejection fraction measured by echocardiography ameliorated significantly at 6-month follow-up (P < 0.05), but difference of the longitudinal variation between two groups was not significant (P > 0.05). When pay attention to left ventricular ejection fraction measured by angiocardiography, difference of the longitudinal variation between groups was significant (P = 0.046). Early diastolic mitral flow velocity deceleration time changed significantly at 6- month follow-up in both groups (P = 0.05).
Conclusions:
Mobilization of stem cells by G-CSF after reperfusion of infarct myocardium is safe and seems to offer a pragmatic strategy for recovery of myocardial global function.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
07:50Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
